FENC

Fennec Pharmaceuticals Inc

Sep 17 • 09:56AM ET

8.78

-0.07 -0.79 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY SRPT AGEN XOMA ACAD NBIX PRQR IONS

| Held by: VTI IWM IWN VTWO IWC IWO RSSL VTWV VTWG OMFS

Index	RUT	P/E	-	EPS (ttm)	-0.42	Insider Own	16.73%	Shs Outstand	27.73M	Perf Week	-2.55%
Market Cap	244.35M	Forward P/E	13.14	EPS next Y	0.67	Insider Trans	-1.33%	Shs Float	23.18M	Perf Month	7.07%
Enterprise Value	243.74M	PEG	-	EPS next Q	0.07	Inst Own	53.27%	Short Float	5.38%	Perf Quarter	13.73%
Income	-11.67M	P/S	7.34	EPS this Y	-	Inst Trans	3.16%	Short Ratio	19.69	Perf Half Y	33.64%
Sales	33.30M	P/B	-	EPS next Y	1570.00%	ROA	-21.61%	Short Interest	1.25M	Perf YTD	38.92%
Book/sh	-0.27	P/C	13.07	EPS next 5Y	-	ROE	-	52W High	9.42 -6.79%	Perf Year	60.51%
Cash/sh	0.67	P/FCF	-	EPS past 3/5Y	71.16% 52.21%	ROIC	-109.79%	52W Low	3.96 121.72%	Perf 3Y	34.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.89%	Volatility	4.67% 4.11%	Perf 5Y	53.77%
Dividend TTM	-	EV/Sales	7.32	EPS Y/Y TTM	-520.08%	Oper. Margin	-29.06%	ATR (14)	0.38	Perf 10Y	188.82%
Dividend Ex-Date	-	Quick Ratio	4.59	Sales Y/Y TTM	-31.88%	Profit Margin	-35.05%	RSI (14)	50.56	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.85	EPS Q/Q	44.00%	SMA20	-0.40%	Beta	0.63	Target Price	14.00
Payout	-	Debt/Eq	-	Sales Q/Q	32.91%	SMA50	1.63%	Rel Volume	0.17	Prev Close	8.85
Employees	32	LT Debt/Eq	-	Earnings	Aug 14 BMO	SMA200	23.30%	Avg Volume	63.33K	Price	8.78
IPO	Oct 22, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	-223.53% 2.34%	Trades		Volume	1,218	Change	-0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-22-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$9 → $12
Sep-07-22	Initiated	CapitalOne	Overweight	$11
Aug-08-22	Resumed	Craig Hallum	Buy	$14
Jun-05-20	Initiated	Cantor Fitzgerald	Overweight	$18
Oct-11-18	Initiated	Goldman	Buy

Aug-14-25 07:20AM	Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -6.37%
06:08AM	Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update (GlobeNewswire)
Aug-13-25 05:15PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +12.00%
Aug-11-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:12AM	Loading…
07:12AM	Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025 (GlobeNewswire)
Aug-07-25 07:05PM	Concentra Group (CON) Matches Q2 Earnings Estimates (Zacks)
Jul-31-25 09:40AM	Are Medical Stocks Lagging Editas Medicine (EDIT) This Year? (Zacks)
Jul-15-25 08:50AM	Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why (Zacks)
Jun-03-25 04:31PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-14-25 10:51AM	The Joint Misses Q1 Earnings Estimates on Rising Expenses (Zacks)
03:07AM	Fennec Pharmaceuticals Inc (FENC) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amid ... (GuruFocus.com)
May-13-25 11:33PM	Q1 2025 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
11:06AM	Acadia Healthcare Q1 Earnings Top Estimates on Rising Admissions (Zacks)
07:15AM	Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:03AM	Loading…
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-12-25 05:10PM	Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.38%
May-09-25 06:26PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) (Zacks)
May-08-25 06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:17PM	Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
May-07-25 05:35PM	Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Zacks)
Apr-30-25 09:55AM	Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High? (Zacks)
Apr-10-25 09:35AM	Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround (Zacks)
Mar-21-25 10:21AM	Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? (Zacks)
Mar-11-25 03:00AM	Fennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:31AM	Q4 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-10-25 06:03AM	Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.19%
Mar-06-25 04:22PM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025 (GlobeNewswire)
Feb-07-25 07:00AM	Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In Germany (GlobeNewswire)
Dec-20-24 06:16AM	Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales (GlobeNewswire)
06:13AM	Loading…
Dec-19-24 06:13AM	Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management (GlobeNewswire)
Dec-12-24 07:01AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-13-24 06:27AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire) +5.91%
Nov-09-24 02:00AM	Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com)
Nov-07-24 06:13AM	Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.92%
Oct-31-24 06:23AM	Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-28-24 06:23AM	Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth (GlobeNewswire) +11.56%
Sep-05-24 06:56AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 01:57AM	Q2 2024 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.89%
Aug-13-24 06:05AM	Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.40%
Aug-06-24 04:31PM	Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 (GlobeNewswire)
Aug-05-24 06:26AM	Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director (GlobeNewswire)
Jul-29-24 06:15AM	3 Dirt-Cheap Stocks Under $10 That Could EXPLODE! (InvestorPlace)
Jul-15-24 08:32AM	Implied Volatility Surging for Fennec (FENC) Stock Options (Zacks)
Jul-01-24 06:00AM	Fennec Pharmaceuticals Announces Management Change (GlobeNewswire)
Jun-25-24 04:35PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
May-15-24 08:44AM	HC Wainwright Adjusts Fennec Pharmaceuticals Price Target to $15 From $18, Maintains Buy Rating (MT Newswires)
May-14-24 10:53AM	FENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -26.75%
07:20AM	Fennec Pharmaceuticals Swings to Q1 Profit on Higher Sales, Licensing Revenue (MT Newswires)
06:03AM	Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 06:15PM	Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 (GlobeNewswire)
Apr-23-24 08:01AM	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing (MT Newswires)
Apr-05-24 07:00PM	Insider Sell: CEO Rosty Raykov Sells 88,583 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-27-24 07:00PM	Chief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-26-24 01:00AM	Chief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC) (GuruFocus.com)
Mar-22-24 09:49AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:04AM	Q4 2023 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-21-24 02:52PM	FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
06:00AM	Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-19-24 10:14AM	Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up (Zacks)
06:01AM	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024 (GlobeNewswire)
Mar-17-24 09:00PM	Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand (GlobeNewswire)
Feb-29-24 07:04AM	Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Feb-01-24 05:55AM	FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin (GlobeNewswire)
Jan-06-24 03:01AM	Insider Sell: CFO Robert Andrade Sells 30,000 Shares of Fennec Pharmaceuticals Inc (GuruFocus.com)
Dec-05-23 05:55AM	Fennec Announces Incremental $5 Million Investment from Petrichor (GlobeNewswire)
Nov-09-23 04:50PM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-23 09:40AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2023 Earnings Call Transcript (Insider Monkey)
02:10AM	Q3 2023 Fennec Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:59AM	Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +15.36%
Oct-30-23 06:45AM	Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire)
Sep-07-23 05:59AM	Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 12:53PM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 05:59AM	Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.29%
Jul-31-23 05:30AM	Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire) +8.66%
Jun-12-23 05:00PM	Fennec Announces Results of Annual Meeting (GlobeNewswire)
Jun-08-23 02:53PM	Retail investors who hold 38% of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) gained 13%, institutions profited as well (Simply Wall St.)
Jun-06-23 05:44AM	Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients (GlobeNewswire)
May-11-23 06:01AM	Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-08-23 06:15AM	Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023 (GlobeNewswire)
Apr-28-23 09:26AM	When Will Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Become Profitable? (Simply Wall St.)
Apr-01-23 08:12AM	Investors in Fennec Pharmaceuticals (NASDAQ:FENC) have made a notable return of 52% over the past three years (Simply Wall St.)
Mar-31-23 08:03AM	Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients (GlobeNewswire)
Mar-30-23 05:55AM	Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)
Feb-23-23 08:44AM	Why Earnings Season Could Be Great for Adherex Technologies (FENC) (Zacks)
Jan-31-23 06:00AM	Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA (GlobeNewswire) +6.26%
Jan-25-23 07:19AM	Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients (GlobeNewswire) +8.27%
Jan-23-23 11:57AM	RTP drugmaker Fennec sues Cipla over generics effort (American City Business Journals)
Dec-17-22 09:55AM	Institutions own 28% of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares but individual investors control 55% of the company (Simply Wall St.)
Nov-11-22 07:10AM	Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-22 10:28AM	Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Are Analysts Optimistic? (Simply Wall St.)
Oct-17-22 08:00AM	Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States (GlobeNewswire)
Sep-26-22 07:35AM	Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor (GlobeNewswire) -8.30%
Sep-21-22 02:19PM	RTP pharma to see $20M infusion on heels of drug winning approval (American City Business Journals) +11.93%
01:05PM	After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss (Benzinga)
07:00AM	Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection) (GlobeNewswire)
06:05AM	U.S. FDA approves Fennec's hearing loss therapy (Reuters)
Aug-22-22 07:04AM	Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor (GlobeNewswire)
Aug-12-22 06:59AM	Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)

Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Raykov Rosty	Director	Sep 05 '25	Option Exercise	2.45	36,207	88,707	87,293	Sep 08 06:05 PM
ROSTISLAV RAYKOV	Director	Sep 04 '25	Proposed Sale	8.92	10,000	89,220		Sep 04 04:37 PM
Raykov Rosty	Director	Sep 04 '25	Sale	8.92	10,000	89,200	51,086	Sep 04 04:10 PM
Raykov Rosty	Director	Aug 05 '25	Sale	8.09	10,000	80,900	55,878	Aug 05 05:33 PM
ROSTISLAV RAYKOV	Director	Aug 05 '25	Proposed Sale	8.09	10,000	80,933		Aug 05 04:14 PM
RALLIS CHRIS A	Director	Jul 07 '25	Option Exercise	2.35	2,127	4,998	55,911	Jul 07 05:31 PM
RALLIS CHRIS A	Director	Jul 07 '25	Sale	8.71	1,119	9,746	54,792	Jul 07 05:31 PM
Raykov Rosty	Director	Jul 03 '25	Sale	8.61	10,000	86,100	60,670	Jul 07 04:30 PM
ROSTISLAV RAYKOV	Director	Jul 03 '25	Proposed Sale	8.61	10,000	86,102		Jul 03 02:01 PM
Raykov Rosty	Director	Jun 05 '25	Sale	7.78	10,000	77,800	65,462	Jun 06 04:20 PM
ROSTISLAV RAYKOV	Director	Jun 05 '25	Proposed Sale	7.78	10,000	77,781		Jun 05 04:31 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	May 22 '25	Option Exercise	5.10	8,220	41,922	158,520	May 23 04:20 PM
Hackman Jeffrey S.	Chief Executive Officer	May 19 '25	Buy	6.99	13,965	97,615	15,000	May 19 05:42 PM
Hackman Jeffrey S.	Chief Executive Officer	May 16 '25	Buy	6.75	1,035	6,986	1,035	May 19 05:42 PM
Raykov Rosty	Director	May 16 '25	Sale	6.78	16,667	113,002	70,254	May 19 04:30 PM
Raykov Rosty	Director	May 16 '25	Proposed Sale	6.01	16,667	100,169		May 16 05:21 PM
Raykov Rosty	Director	May 05 '25	Sale	6.31	10,000	63,100	53,587	May 05 06:23 PM
ROSTISLAV RAYKOV	Director	May 05 '25	Proposed Sale	6.31	10,000	63,078		May 05 04:01 PM
Raykov Rosty	Director	Apr 04 '25	Sale	5.25	10,000	52,500	61,156	Apr 04 07:29 PM
ROSTISLAV RAYKOV	Director	Apr 04 '25	Proposed Sale	5.25	10,000	52,537		Apr 04 04:12 PM
Raykov Rosty	Director	Mar 05 '25	Sale	6.79	10,000	67,900	68,725	Mar 06 05:32 PM
ROSTISLAV RAYKOV	Director	Mar 05 '25	Proposed Sale	6.79	10,000	67,930		Mar 05 04:29 PM
RALLIS CHRIS A	Director	Feb 14 '25	Option Exercise	2.51	1,992	5,000	54,206	Feb 14 06:13 PM
RALLIS CHRIS A	Director	Feb 14 '25	Sale	6.82	1,186	8,089	53,020	Feb 14 06:13 PM
CHRIS A RALLIS	Director	Feb 14 '25	Proposed Sale	6.82	1,186	8,089		Feb 14 04:03 PM
Raykov Rosty	Director	Feb 05 '25	Sale	6.66	10,000	66,600	76,294	Feb 05 08:24 PM
ROSTISLAV RAYKOV	Director	Feb 05 '25	Proposed Sale	6.66	10,000	66,558		Feb 05 04:42 PM
Raykov Rosty	Director	Jan 06 '25	Sale	6.08	10,000	60,800	83,863	Jan 07 05:15 PM
ROSTISLAV RAYKOV	Director	Jan 06 '25	Proposed Sale	6.08	10,000	60,847		Jan 06 04:19 PM
Raykov Rosty	Director	Dec 20 '24	Option Exercise	2.69	25,000	67,250	91,432	Dec 23 05:00 PM
Raykov Rosty	Director	Dec 05 '24	Sale	6.04	796	4,808	66,432	Dec 05 04:24 PM
ROSTISLAV RAYKOV	Director	Dec 05 '24	Proposed Sale	6.04	796	4,808		Dec 05 04:00 PM
Raykov Rosty	Director	Dec 03 '24	Sale	6.13	1,635	10,023	67,228	Dec 04 05:20 PM
ROSTISLAV RAYKOV	Director	Dec 03 '24	Proposed Sale	6.13	1,635	10,023		Dec 03 04:03 PM
RALLIS CHRIS A	Director	Dec 02 '24	Option Exercise	2.69	10,000	26,900	58,623	Dec 02 07:07 PM
RALLIS CHRIS A	Director	Dec 02 '24	Sale	6.14	6,409	39,351	52,214	Dec 02 07:07 PM
CHRIS A RALLIS	Director	Dec 02 '24	Proposed Sale	6.14	6,409	39,344		Dec 02 04:06 PM
Andrade Robert	CHIEF FINANCIAL OFFICER	Nov 18 '24	Option Exercise	2.45	15,816	38,749	127,381	Nov 18 05:02 PM
Raykov Rosty	Director	Nov 04 '24	Sale	4.31	2,431	10,478	66,432	Nov 04 05:30 PM
ROSTISLAV RAYKOV	Director	Nov 04 '24	Proposed Sale	4.31	2,431	10,478		Nov 04 04:02 PM
RALLIS CHRIS A	Director	Oct 08 '24	Option Exercise	2.55	1,960	4,998	50,029	Oct 10 05:14 PM
RALLIS CHRIS A	Director	Oct 08 '24	Sale	4.53	1,406	6,369	48,623	Oct 10 05:14 PM
Raykov Rosty	Director	Oct 01 '24	Sale	4.94	2,431	12,009	66,432	Oct 01 05:11 PM
ROSTISLAV RAYKOV	Director	Oct 01 '24	Proposed Sale	4.94	2,431	12,009		Oct 01 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FENC

Fennec Pharmaceuticals Inc

Upgrade your FINVIZ experience